R&D is 74.9% of revenue for the period ending 30 Sep 2026.
What should Autolus publish next: indication, endpoints, or timeline?
R&D is 74.9% of revenue for the period ending 30 Sep 2026.
What should Autolus publish next: indication, endpoints, or timeline?
• Holder: Blackstone
• Stake: now 7.6% (about $27M)
• Filed: Nov 10 · Schedule 13D/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#ActivistInvesting #Stocks #Investing #ElixStocks
• Holder: Blackstone
• Stake: now 7.6% (about $27M)
• Filed: Nov 10 · Schedule 13D/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#ActivistInvesting #Stocks #Investing #ElixStocks
https://www.stocktitan.net/news/AUTL/autolus-therapeutics-reports-third-quarter-2026-financial-results-aeb4ctdhp20w.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AUTL/autolus-therapeutics-reports-third-quarter-2026-financial-results-aeb4ctdhp20w.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AUTL/autolus-therapeutics-presents-longer-term-follow-up-data-from-i1gh1ddbn98o.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AUTL/autolus-therapeutics-presents-longer-term-follow-up-data-from-i1gh1ddbn98o.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AUTL/autolus-therapeutics-to-participate-in-the-jefferies-global-9dg2arxkhv7z.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AUTL/autolus-therapeutics-to-participate-in-the-jefferies-global-9dg2arxkhv7z.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AUTL/autolus-therapeutics-to-present-clinical-data-updates-at-the-bj16k5pcl939.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AUTL/autolus-therapeutics-to-present-clinical-data-updates-at-the-bj16k5pcl939.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AUTL/autolus-therapeutics-announces-inducement-grants-under-nasdaq-lcpxaqpjufkh.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AUTL/autolus-therapeutics-announces-inducement-grants-under-nasdaq-lcpxaqpjufkh.html?utm_source=stocktitan-bluesky&utm_medium=social
New hub updated: www.merlintrader.com/autolus-ther...
New hub updated: www.merlintrader.com/autolus-ther...
New hub updated: www.merlintrader.com/autolus-ther...
New hub updated: www.merlintrader.com/autolus-ther...
Information only — not investment advice.
https://www.merlintrader.com/autolus-therapeutics-stock-hub/
Information only — not investment advice.
https://www.merlintrader.com/autolus-therapeutics-stock-hub/
https://www.stocktitan.net/news/AUTL/autolus-therapeutics-to-report-third-quarter-2026-financial-results-0dp66s7tbggp.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AUTL/autolus-therapeutics-to-report-third-quarter-2026-financial-results-0dp66s7tbggp.html?utm_source=stocktitan-bluesky&utm_medium=social
Friday -7.0% to $1.60 on 2.35M shares.
Lupus follow-up at ACR; ALARIC data by year-end.
Support $1.17 / resistance $1.68.
Hub: www.merlintrader.com/autolus-ther...
Friday -7.0% to $1.60 on 2.35M shares.
Lupus follow-up at ACR; ALARIC data by year-end.
Support $1.17 / resistance $1.68.
Hub: www.merlintrader.com/autolus-ther...
https://financialreportinsights.com/companies/autl/2026/q2
https://financialreportinsights.com/companies/autl/2026/q2
Autolus (#$AUTL): Can AUCATZYL Sustain Its Commercial Momentum?
www.merlintrader.com/autolus-ther...
Autolus (#$AUTL): Can AUCATZYL Sustain Its Commercial Momentum?
www.merlintrader.com/autolus-ther...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/autolus-ther...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/autolus-ther...
Autolus Therapeutics secured Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration f…
Read more: https://embers.news/article/autolus-secures-fda-rmat-status-for-obe-cel-in-lupus-treatment-60452
Autolus Therapeutics secured Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration f…
Read more: https://embers.news/article/autolus-secures-fda-rmat-status-for-obe-cel-in-lupus-treatment-60452